GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Price-to-Owner-Earnings

Sensei Biotherapeutics (Sensei Biotherapeutics) Price-to-Owner-Earnings : (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Price-to-Owner-Earnings?

As of today (2024-05-23), Sensei Biotherapeutics's share price is $1.45. Sensei Biotherapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sensei Biotherapeutics's Price-to-Owner-Earnings or its related term are showing as below:


SNSE's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.67
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-23), Sensei Biotherapeutics's share price is $1.45. Sensei Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.21. Therefore, Sensei Biotherapeutics's PE Ratio for today is At Loss.

As of today (2024-05-23), Sensei Biotherapeutics's share price is $1.45. Sensei Biotherapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.20. Therefore, Sensei Biotherapeutics's PE Ratio without NRI for today is At Loss.


Sensei Biotherapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Sensei Biotherapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Price-to-Owner-Earnings Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Sensei Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sensei Biotherapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Sensei Biotherapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Price-to-Owner-Earnings falls into.



Sensei Biotherapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sensei Biotherapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.45/-1.36
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sensei Biotherapeutics  (NAS:SNSE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sensei Biotherapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.
Executives
Stephanie Krebs officer: Chief Business Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi director, officer: President & CEO SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer director, 10 percent owner C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc 10 percent owner, other: See Remarks 228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p. other: See Explanation of Responses 340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c. 10 percent owner 340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher officer: Chief Business Officer 66 HAROLD ST, BOSTON MA 02119
William R Ringo director
Thomas G Ricks director H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce officer: Chief Scientific Officer C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer director C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English director C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850

Sensei Biotherapeutics (Sensei Biotherapeutics) Headlines

From GuruFocus

Sensei Biotherapeutics Provides Update on Strategic Priorities

By Value_Insider Value_Insider 12-08-2022